ChangChun High New Technology Industries operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares ChangChun High New Technology Industries with three other
companies in this sector in China:
Shandong Lukang Pharmaceutical
sales of 2.51 billion Chinese Renmimbi [US$388.76 million]
of which 67%
was Human Antibiotic),
Hunan ER-KANG Pharmaceutical Co Ltd
(2.96 billion Chinese Renmimbi [US$459.47 million]
of which 92%
was Manufacture of Medicines), and
Shanxi Zhendong Pharmaceutical Co Ltd
(3.28 billion Chinese Renmimbi [US$509.32 million]
of which 94%
was Medicine Manufacture and Sale).
During the year ended December of 2016, sales at
ChangChun High New Technology Industries were 2.87 billion Chinese Renmimbi (US$445.97 million).
increase of 21.0%
versus 2015, when the company's sales were 2.37 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at ChangChun High New Technology Industries
(and since 2011, sales have increased a total of 122%).
Sales of Medication saw an increase
22.8% in 2016, from
1.89 billion Chinese Renmimbi to 2.32 billion Chinese Renmimbi.
Not all segments of ChangChun High New Technology Industries experienced an increase in sales in 2016:
sales of Service Industry fell 5.7% to 35.34 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).